This year, we are seeing a major boost in the advancement of new targeted gene therapies in the fight against certain orphan ocular genetic diseases that cause blindness. The progressive introduction of computer tools with algorithms for the recognition of diabetic retinopathy should be noted. Progress has been made in other areas of ophthalmology, with particular interest in the fight against myopia, given the worrying and rapidly increasing incidence of this disease, in varying proportions throughout the world. There has also been a major effort to develop new ways of delivering specific ocular treatments without having to rely on patient compliance. Finally, we are discovering new diagnostic and clinical entities related to the side effects of systemic immunotherapy generally used in oncology.